Stock URGN UROGEN PHARMA LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages UroGen Pharma Ltd.

Equities

URGN

IL0011407140

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
14.15 USD +2.39% Intraday chart for UroGen Pharma Ltd. +3.06% -5.67%
04-15 UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment MT
04-03 UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
UroGen Pharma Says FDA Accepts Investigational New Drug Application for Potential Bladder Cancer Treatment
UroGen Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
UroGen Pharma Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
UroGen Pharma Starts Rolling NDA Submission for Bladder Cancer Drug
UroGen Pharma Ltd. Initiates Submission of a Rolling NDA to the FDA for UGN-102
Urogen Pharma Ltd. Enters into A License and Supply Agreement (The Agreement) with Medac Gesellschaft Für Klinische Spezialpräparate m.b.H
UroGen Pharma Ltd. Plans to Initiate Phase 3 Study in 2024
UroGen Signs Licensing Deal With Medac to Develop New Formulation for Urothelial Cancer; Shares Rise
UroGen Pharma Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
UroGen Pharma Ltd. Reiterates Revenue Guidance for the Full Year 2023
UroGen Pharma Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023
UroGen Pharma Shares Surge Amid Data From Bladder Cancer Drug Trials, $120 Million Private Stock Sale
UroGen Pharma Ltd. Announces Positive Topline Data From its Phase 3 Trials ATLAS and ENVISION studying UGN-102
UroGen Pharma Ltd. Announces the Appointment of James Robinson to Its Board of Directors
UroGen Pharma Ltd. Announces Retrospective Study Finds Jelmyto Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors That Impede Kidney Preservation
Urogen Pharma Ltd. Announces the Results of Sub-Analysis from the First Post- Commercial Utilization Review of Jelmyto®? Forpyelocalyceal Solution
UroGen Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023
UroGen Announces New Retrospective Study Presented
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. URGN Stock
  4. News UroGen Pharma Ltd.
  5. Other languages